Effect of rt-PA thrombolysis combined with antiplatelet therapy on recurrent cardiovascular and cerebrovascular events in patients with mild acute ischemic stroke
10.3760/cma.j.issn.1008-6706.2019.04.020
- VernacularTitle:阿替普酶静脉溶栓联合抗血小板治疗对急性缺血性轻型脑卒中患者心脑血管不良事件再发的影响
- Author:
Huawei LIU
1
;
Feng YE
Author Information
1. 绍兴市中心医院全科医学科 312000
- Keywords:
Acute ischemic stroke;
Recombinant human tissue plasminogen activator;
Intravenous thrombolysis;
Antiplatelet;
Cardiovascular and cerebrovascular adverse event;
Liver function;
Renal function;
Barthel index scale;
Modified Rankin scale
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(4):461-465
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect of recombinant human tissue plasminogen activator(rt-PA) intravenous thrombolytic therapy combined with antiplatelet therapy on the recurrence of cardio cerebral vascular adverse events in patients with mild acute ischemic stroke (AIS).Methods From December 2015 to December 2017,74 patients with mild AIS treated in Shaoxing Central Hospital were selected in the research.According to the random number table method,the patients were divided into two groups,with 37 cases in each group.The control group received rt-PA intravenous thrombolysis,and the combined group was treated with antiplatelet therapy on the basis of the control group.The serum creatinine(SCr),alanine transaminase(ALT) and platelet count(PLT) were compared before and after treatment in the two groups,and the scores of the Barthel index scale and the modified Rankin scale were compared between the two groups.The incidence of cardiovascular adverse events in 3 months of the two groups was also recorded.Results There were no statistically significant differences in liver and kidney function indicators between the two groups before and after treatment (t =0.30,0.27,0.20,0.77,0.03,0.64,all P ＞ 0.05).Before treatment,the Barthel index scale scores in the combined group and control group[(74.97 ±4.74)points,(61.95 ± 4.24) points] were significantly increased,and the increasing degree in the combined group was more significant than that in the control group(t =12.45,P ＜ 0.05).The modified Rankin scale scores in the combined group and control group[(1.16 ± 0.37) points,(2.05 ± 0.45) points] were significantly decreased compared with those before treatment,and the reduction degree of the combined group was more significant than that in the control group(t =9.29,P ＜ 0.05).The total incidence rate of bleeding events,cardiovascular events,cerebrovascular events and death events in the combined group(5.41％) was significantly lower than that of the control group(27.03％) (x2 =4.87,P ＜ 0.05).Conclusion rt-PA intravenous thrombolytic therapy combined with antiplatelet therapy can effectively improve the nerve function and daily activity of patients with mild AIS.It can also effectively reduce the incidence of cardiovascular and cerebrovascular adverse events,and thus help to improve the prognosis and improve the quality of life.Therefore,it has good clinical application value.
